FDA Approves Pneumococcal Disease Vaccine with Broader Protection
Links shared publicly online about this topic.
- 1,358total visits
FDA Approves Pneumococcal Disease Vaccine with Broader Protection
fda.gov —
View full resource at fda.gov
Tags: Pneumococcal Disease, Pneumococcal Vaccine, Disease and Condition, Drug, Children's Health, FDA, Vaccine, Prevnar
Most Recently Shared on February 25, 2010 at 5:19 pm By:
FDA approves new #Pneumococcal Vaccine with Broader Protection for infants, toddlers http://bit.ly/9as7JB #pediatrics #Prevnar
Symposier - New Pneumococcal Vaccine for Children
symposier.com — “Uploaded and Shared in Youtube by: USFoodandDrugAdmin FDA has approved a new pneumococcal vaccine that provides broader protection for infants and young children ages six weeks through five years. The new vaccine, called Prevnar 13, is effective against 13 serotypes of the bacterium Streptococcus pneumoniae. It will replace Prevnar, which was effective against seven serotypes. Prevnar 13 is approved to prevent invasive pneumococcal disease, including bacterial meningitis and bacteremia, caused b” View full resource at symposier.com
Most Recently Shared on May 21, 2010 at 6:04 pm By:
FDA - New Pneumococcal Vaccine for Children. http://bit.ly/cML6lF
PCV13 vaccine may have big effect among young children - Related Stories - AAP SmartBrief
smartbrief.com — “A CDC report said a recently approved broader pneumococcal vaccine could significantly reduce the rate of disease in young children. The FDA approved the PCV13 vaccine last month, and it covers pneumococcal strains that were responsible for 64% of pneumococcal cases in children under age 5 in 2007.” View full resource at smartbrief.com
Most Recently Shared on March 12, 2010 at 8:04 pm By:
Clara Song Doctor, Pediatrician, and Physician
PCV13 vaccine may have big effect among young children http://sbne.ws/r/42Wj
FDA Approves Pneumococcal Disease Vaccine With Broader Protection
medicalnewstoday.com — “The U.S. Food and Drug Administration approved Prevnar 13, a pneumococcal 13-valent conjugate vaccine for infants and young children ages 6 weeks through 5 years. Prevnar 13 will be the successor” View full resource at medicalnewstoday.com
Most Recently Shared on February 25, 2010 at 2:55 pm By:
FDA Approves Pneumococcal Disease Vaccine With Broader Protection The U.S. Food and Drug Administration approved Prev.. http://bit.ly/adkhzF
Advertisement
